Pazopanib

製品コードS3012 別名:GW786034

Pazopanib化学構造

分子量(MW):437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 11620.00
JPY 34860.00
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

カスタマーフィードバック(5)

  • Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib purchased from Selleck.

    J Virol 2011 85(5), 2296-303. Pazopanib purchased from Selleck.

  • Arch Toxicol, 2018, 92(4):1435-1451. Pazopanib purchased from Selleck.

    (a,b) Effect of Pazopanib on vascular network integrity. VMOs were exposed to drug from day 4 to 6. Data are normalized to day of first drug exposure and are shown as percentage of control. Error bars show mean ± s.d (n = 3) (p < 0.05 vs control).

    Sci Rep, 2016, 6:31589. Pazopanib purchased from Selleck.

  • (B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

    Transl Oncol, 2016, 9(3):197-202. Pazopanib purchased from Selleck.

製品安全説明書

VEGFR阻害剤の選択性比較

生物活性

製品説明 Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
ターゲット
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
体外試験

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell M1\pbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHT2cpFKdmirYnn0bY9vKG:oIHj1cYFvKEWxTD2xMYNmdGxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygbYM2OD1{Lki5[U0xPSEQvF2= M2PxSnNCVkeHUh?=
human AN3-CA cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYTRS|BOUW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5yNTDuUS=> NV7UcnY5W0GQR1XS
human CGTH-W-1 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnzhTY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQxNjBzIH7N MWHTRW5ITVJ?
human GDM-1 cell NXf3XpdxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGraXYNKdmirYnn0bY9vKG:oIHj1cYFvKEeGTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVA{Njl7IH7N MkHnV2FPT0WU
human A204 cell NFviVYFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4fZUGlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwPU4xPiCwTR?= NXPISXF[W0GQR1XS
human G-402 cell NHvHNHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWXJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUOxMlg1KG6P M1;qcXNCVkeHUh?=
human MFE-296 cell M2\FeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFrvXoFKdmirYnn0bY9vKG:oIHj1cYFvKE2IRT2yPVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjV7MEKyJO69VQ>? MV3TRW5ITVJ?
human NOS-1 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF\vSYRKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKGmlNUC9NE43PTl6NzFOwG0> MkfyV2FPT0WU
human KG-1 cell M3vzeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXuxPJRpUW6qaXLpeIlwdiCxZjDoeY1idiCNRz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OTd3NTFOwG0> NV3QN3ZtW0GQR1XS
human HT55 cell M2HnSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MknuTY5pcWKrdHnvckBw\iCqdX3hckBJXDV3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65PFc5OSEQvF2= MoX6V2FPT0WU
human MG-63 cell NEW0Z4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXHJcohq[mm2aX;uJI9nKGi3bXHuJG1INTZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6wNFE1PiEQvF2= NFH2[oNUSU6JRWK=
human CCF-STTG1 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NES3bpdKdmirYnn0bY9vKG:oIHj1cYFvKEOFRj3TWHRIOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G778{MJGlEPTB;MT6wOFk5OSEQvF2= MUjTRW5ITVJ?
human RT-112 cell MnLuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHLPPFhKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTB|N{[g{txO Moe1V2FPT0WU
human MC-IXC cell NG[ydFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF;jdmpKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTF3MUKg{txO NWDKVI9QW0GQR1XS
human HUTU-80 cell NHXITW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWTtTWRZUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OEGwN{DPxE1? MmjNV2FPT0WU
human MV-4-11 cell NYrFSXB[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEHZUFBKdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjN2NUCxJO69VQ>? M4TmS3NCVkeHUh?=
human LCLC-103H cell NGm3d4NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnHoTY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUGwN2gh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigQ>? M3jodnNCVkeHUh?=
human G-401 cell M1q3fGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnyyTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFY1OjFizszN MYPTRW5ITVJ?
human A704 cell M3u0Zmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3\FZWlvcGmkaYTpc44hd2ZiaIXtZY4hSTdyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlA{OjNizszN Mli1V2FPT0WU
human ESS-1 cell M4LEVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYPJcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NFM6PiEQvF2= NGTOfYNUSU6JRWK=
human HLE cell M1HDXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYPJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNkO4NFQh|ryP M13kOHNCVkeHUh?=
human NY cell NVrEWo1JT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGrLR4pKdmirYnn0bY9vKG:oIHj1cYFvKE6\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT64OFgzOSEQvF2= NUjYcWtvW0GQR1XS
human A427 cell NV;GVYZKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFHBdWFKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk5ODd3IN88US=> M{T1V3NCVkeHUh?=
human SK-N-DZ cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4C5bmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3EXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODJ|OEGg{txO NVzVWYEzW0GQR1XS
human J82 cell M1zKRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJGo5OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwME[wPFgh|ryP NXz1cJk6W0GQR1XS
human GI-1 cell NXLFbpFtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1zsSGlvcGmkaYTpc44hd2ZiaIXtZY4hT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNlI6PTFizszN MoS0V2FPT0WU
human NCI-H716 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXrJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{G2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{OTZ|MzFOwG0> Mm\MV2FPT0WU
human SF126 cell NEe3cllIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoLRTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOFc1PTlizszN M{TlUnNCVkeHUh?=
human H4 cell NVv5OZFbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIf1NXZKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61NVI3OiEQvF2= MojiV2FPT0WU
human LB831-BLC cell NW\mNmh4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoDyTY5pcWKrdHnvckBw\iCqdX3hckBNSjh|MT3CUGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjV2NU[2JO69VQ>? M1S2N3NCVkeHUh?=
human HCC1395 cell NV\2[|MyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVXJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF|OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU5OTV4IN88US=> MmDSV2FPT0WU
human LK-2 cell NIH4XXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnLWTY5pcWKrdHnvckBw\iCqdX3hckBNUy1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj62OFU3QSEQvF2= M4jMZ3NCVkeHUh?=
human G-361 cell M1XWNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYS2TXNXUW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODRyOEKg{txO M1PqPHNCVkeHUh?=
human NCI-H2342 cell NYX3VIlkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoDITY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzOFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS5iSVO1NF0{NjF|M{G2JO69VQ>? MmHOV2FPT0WU
human SK-LU-1 cell  NGfacllIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVzJcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyXLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlE5PzZ5IN88US=> NIPUSphUSU6JRWK=
human IGROV-1 cell  MljaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1vaPGlvcGmkaYTpc44hd2ZiaIXtZY4hUUeUT2[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjR5MUOg{txO MmT3V2FPT0WU
human EB2 cell NU\pdlMxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGXENnpKdmirYnn0bY9vKG:oIHj1cYFvKEWEMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlgyPjhizszN MUDTRW5ITVJ?
human CAL-54 cell NGXWVWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVzJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlg{PjdizszN M1jwOXNCVkeHUh?=
human LB1047-RCC cell NEnNb|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mlm3TY5pcWKrdHnvckBw\iCqdX3hckBQS1WELV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlM{OTN4ODFOwG0> NXXZW2NvW0GQR1XS
Daudi cell MmHiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHXlZmxKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkWzNVY1KM7:TR?= NH;pcYZUSU6JRWK=
human Daudi cell NETMU3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWDJcohq[mm2aX;uJI9nKGi3bXHuJGRifWSrIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62OlIyQSEQvF2= MnLPV2FPT0WU
human A172 cell NEDifnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mlj3TY5pcWKrdHnvckBw\iCqdX3hckBCOTd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz63N|c6KM7:TR?= NFfmV2ZUSU6JRWK=
human KGN cell M3nGdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFewXFFKdmirYnn0bY9vKG:oIHj1cYFvKEuJTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNFY4ODlizszN MkDxV2FPT0WU
human SNG-M cell NUnZdIJqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MULJcohq[mm2aX;uJI9nKGi3bXHuJHNPTy2PIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6wPFY3QSEQvF2= NXLnNpVWW0GQR1XS
human SW1710 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXzJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOFc{OThizszN NGPDdJBUSU6JRWK=
human HT29 cells MlzTVJJwdGmoZYLheIlwdiCjc4PhfS=> M2jQRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSyPUBk\WyuczDpckB{\XK3bTDjc451[WmwaX7nJI1m\Gm3bR?= MlnhNVg3OjB|OEK=
human A375P cells M37LcnBzd2yrZnXyZZRqd25iYYPzZZk> MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF|N{XQJINmdGy|IHnuJJNmenWvIHPvcpRicW6rbnegcYVlcXWv MYSxPFYzODN6Mh?=
human HN5 cells M3zCXnBzd2yrZnXyZZRqd25iYYPzZZk> MnvBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTkWgZ4VtdHNiaX6gd4VzfW1iY3;ueIFqdmmwZzDt[YRqfW1? MUOxPFYzODN6Mh?=
HUVEC NXHrbldnTnWwY4Tpc44h[XO|YYm= M36xbVEh|ryP M33wV|YhcA>? Ml;0RY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dXLlJIZwem2jdHnvckBifCByLkGgeW0h[W[2ZYKgOkBpenNiYomgUYF1emmpZXygZZN{[Xl? MXyyOFA{PjB2Mh?=
human Daoy cell NUDBdVlxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFvZclBKdmirYnn0bY9vKG:oIHj1cYFvKESjb4mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc4QTR7IN88US=> MXjTRW5ITVJ?
human DMS-273 cell M1Xiemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4r0SmlvcGmkaYTpc44hd2ZiaIXtZY4hTE2VLUK3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTZ{MEKg{txO MnHKV2FPT0WU
human KU812 cell NU\uN21QT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1TDbWlvcGmkaYTpc44hd2ZiaIXtZY4hU1V6MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM4QDF{IN88US=> MnnOV2FPT0WU
human NCI-H727 cell NWK2dY43T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{K3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41ODlyMTFOwG0> M3juUXNCVkeHUh?=
human P30-OHK cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoX5TY5pcWKrdHnvckBw\iCqdX3hckBROzBvT1jLJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41Pjl2IN88US=> NXHrVnU3W0GQR1XS
human MIA-PaCa-2 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnPJTY5pcWKrdHnvckBw\iCqdX3hckBOUUFvUHHDZU0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54MES2OkDPxE1? MVnTRW5ITVJ?
human TT cell NFq0PHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUDJcohq[mm2aX;uJI9nKGi3bXHuJHRVKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54NkK0JO69VQ>? MkHVV2FPT0WU
human DK-MG cell NUfVT25KT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV7LcnpqUW6qaXLpeIlwdiCxZjDoeY1idiCGSz3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzJyMkig{rxu NGXEd2lUSU6JRWK=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

お薦めの試験操作(参考用のみ)

動物試験:

[2]

+ 展開
  • 動物モデル: Immunodeficient mice bearing SYO-1 cells
  • 製剤: --
  • 投薬量: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • 投与方法: Oral administration
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 87 mg/mL (198.84 mM) warming
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 437.52
化学式

C21H23N7O2S

CAS No. 444731-52-6
保管
in solvent
別名 GW786034

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03850730 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Cure HHT|University of North Carolina September 2019 Phase 1|Phase 2
NCT03850964 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Nosebleed|Anemia Cure HHT September 2019 Phase 2|Phase 3
NCT03850730 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Cure HHT|University of North Carolina September 2019 Phase 1|Phase 2
NCT03850964 Not yet recruiting Hereditary Hemorrhagic Telangiectasia|Epistaxis Nosebleed|Anemia Cure HHT September 2019 Phase 2|Phase 3
NCT03660930 Not yet recruiting Soft Tissue Sarcoma University of Washington April 1 2019 Phase 1|Phase 2
NCT03660930 Not yet recruiting Soft Tissue Sarcoma University of Washington April 1 2019 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

VEGFRシグナル伝達経路

相関VEGFR製品

Tags: Pazopanibを買う | Pazopanib ic50 | Pazopanib供給者 | Pazopanibを購入する | Pazopanib費用 | Pazopanib生産者 | オーダーPazopanib | Pazopanib化学構造 | Pazopanib分子量 | Pazopanib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID